Filing Flows › BioXcel Therapeutics (BTAIQ) › Q2 2025
BioXcel Therapeutics (BTAIQ) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
BioXcel Therapeutics (BTAIQ) reported revenue of $120K for the second quarter 2025 (Q2 2025), -89% from a year earlier and -29% from the quarter before.
BioXcel Therapeutics, Q2 2025: revenue $120K (-89% year over year), net loss $19.2M, operating cash flow −$12.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $120K | -29% | -89% |
| Operating profit | −$15.9M | — | — |
| Net earnings | −$19.2M | — | — |
| Operating cash flow | −$12.6M | — | — |
What changed
Revenue was $120K in Q2 2025, down 89% year over year and down 29% from the previous quarter.
Operating costs exceeded revenue by $15.9M, an operating margin of -13210.0%. Total costs fell 13% while revenue fell 89%. The fastest-growing cost line was Cost of revenue (+73%). The quarter ended with a net loss of $19.2M, wider than the previous quarter's $7.3M loss.
Operating cash flow was −$12.6M. Non-cash charges added back $75K of depreciation and $1.6M of share-based compensation. Working capital and other items added $5.0M.
Questions
What was BioXcel Therapeutics' revenue in the second quarter 2025?
BioXcel Therapeutics (BTAIQ) reported revenue of $120K for the second quarter 2025 (Q2 2025), -89% from a year earlier and -29% from the quarter before.